Mr. Crowe is the founder of NuView Life Sciences and has served as Chairman and Chief Executive Officer since 2005. Mr. Crowe’s experience includes early-stage company development, strategic planning, capital formation, M&A, and public offerings. Over the past 40 years, Mr. Crowe has commercialized novel medical imaging technologies, such as diagnostic ultrasound with Philips Medical Systems, magnetic resonance imaging (MRI) with Diasonics NMR and positron emission tomography (PET) with Mobile PET Systems. Mr. Crowe developed several medical service provider businesses utilizing the technologies described above building high-performance management, sales and operations teams to drive technology adoption and revenue growth.

Dr. Dowd brings to the Company over 11 years of drug development experience in the Pharmaceutical industry.  Dr. Dowd has served in a variety of roles during his career, including preclinical research in Oncology and Alzheimer’s Disease, strategic planning, clinical development, medical affairs, and in-licensing.  Prior to joining NuView Life Sciences, Dr. Dowd served as Associate Director of Clinical and Scientific Affairs at Myrexis, Inc. (previously Myriad Pharmaceuticals Inc.) and preclinical drug development positions at Sugen, Inc.  He graduated from the University of Michigan, Ann Arbor with a B.S. in Biology and earned his Ph.D. at the Yale University School of Medicine in the Department of Cellular and Molecular Physiology.

Mr. Brown has over 40 years of business and financial experience in the analysis, structuring and sourcing of capital, valuation, repositioning/restructuring and the management of financial/operating assets, as well as, businesses. Mr. Brown is the founding partner of three investment-banking firms, a private equity firm, and two investment management firms. Mr. Brown has served as the CFO of several public and private companies, as well as, non-profit organization and focused on coordinating the reporting and management of the financial infrastructure for emerging growth businesses and organizations. In addition to serving on the board of several public, private and non-profit organizations, Mr. Brown has been the chairman of the audit committees of several public companies.   Mr. Brown graduated from the University of Southern California with a B.S. in Finance and earned the Chartered Financial Analyst (CFA) designation.  Mr. Brown is an Adjunct Professor in the Argyros School of Business & Finance at Chapman University where he teaches Entrepreneurial Finance.

Mr. Davis has over twenty years’ experience in corporate, securities, and business law, with extensive experience in emerging growth companies.  Mr. Davis is also a founding partner of Rancho Santa Fe Partners, a strategic advisory firm that supports emerging growth companies.  Mr. Davis has served as General Counsel and an executive officer for several public and privately held companies, and has clients which include International Stem Cell (ISCO), Amylin Pharmaceuticals (AMLN), Leap Wireless (LEAP), BillMyParents (BMPI), Mitek (MITK), and SugarMade (SGMD).  Mr. Davis is on the Board of Directors and Audit, Compensation and Nominating Committees (Chairman) of Telanetix (TNIX), a publicly traded telecommunications company, and on the Board of Directors of Theragene, a privately held life sciences company.  Mr. Davis practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP, where he advised both private and public clients in a variety of transactions.  Mr. Davis received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law. He received his B.A. in Political Science, Cum Laude, from Arizona State University.

Dr. Conti has served as the Company’s Medical Director and Director of the Company since October 2004.  Dr. Conti is a Professor of Radiology, Pharmacy, and Biomedical Engineering at the University of Southern California, as well as Director of its Positron Imaging Science Center and Clinic. Dr. Conti received his medical degree from Cornell University and completed his residency in Diagnostic Radiology and fellowship in Nuclear Medicine at The Johns Hopkins Medical Institution. He is board-certified in both Diagnostic Radiology and Nuclear Medicine. Dr. Conti currently serves on the Board of Directors and is a past-president of the Society of Nuclear Medicine (SNM). Dr Conti also serves on a number of committees for the SNM that is focused on the development of the PET technology and its applications in medicine, including those involving government and regulatory affairs.

Mr. Foster brings to the Company’s board a strong management background in various aspects of the healthcare industry. From 2000-2008, Mr. Foster served as Corporate Vice President of Edwards Life Sciences and coordinated the spin-off of Edwards from Baxter International into a NYSE listed company in April 2001. Mr. Foster was president Global Operations for Baxter International from 1994 to 2000, where he managed the vascular and critical care business. From 1990 to 1994, Mr. Foster was president of Intramed Laboratories, a venture funded development Stage Company, which was focused on developing the technology for disposable endoscopy products that subsequently went public and was sold to Baxter International. In 1983 to 1989, he was vice president and general manager of Sensor medics, the advanced technology operations group of Beckman Instruments, where he coordinated a leverage buyout of the business that became the leader in anesthesia monitoring and exercise physiology equipment and was subsequently sold to Thermo-Electron.

Mr. McCausland joined the Company as a Director in October 2007. Over Mr. McCausland’s 40-year business career, he has served in senior executive positions with Westinghouse Electric Corporation and Siemens. From 1997 through 2006, he served as President of the Siemens Medical Customer Solutions Group and grew revenues from $1 billion to over $4 billion during his tenure. In addition to serving as an advisor to the Radiological Society of North America and several other healthcare companies, Mr. McCausland also served as chairman of the Siemens Foundation dedicated to improving math and science education in high schools.

Michael Nobel participated in the introduction of magnetic resonance imaging in 1980 and remained in that field for 26 years. Today he is chairman or board member of seven international companies in diagnostics, treatment and information systems in the field of medicine.

For 15 years Michael Nobel represented the Nobel family as vice chairman and chairman of its board of directors. He is founder and chairman of the Nobel Sustainable Trust.  He is chairman or board member of eight non-for-profit organizations in the field of youth education and development and peace and conflict resolution.

Michael Nobel was visiting professor at the Frontier Research Institute at the Tokyo Institute of Technology between 2007 and 2012. He is currently a senior fellow at the Centre for the Study of World Civilizations at Tokyo Tech and a guest professor at Seisa University.

In 2005 in Jerusalem he received the Albert Einstein Medal for Outstanding Achievements in Life Sciences and Technology and in 2006 the International Order of Perfection in Moscow. In 2013 he received the Order of Duty and Honor from the United Nations Council for Public Awards and the Gold Medal from the IINC in Tambov, Russia. The World Federation of Consuls presented him its Order of Merit in 2014.

Michael Nobel obtained a doctorate at the University of Lausanne in psycho-pedagogy.